Drug Type Antibody drug conjugate (ADC) |
Synonyms DFRF 4539A, DFRF-4539A, RG 7598 + [2] |
Target |
Action inhibitors |
Mechanism FCRL5 inhibitors(Fc receptor-like protein 5 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Multiple Myeloma | Phase 1 | United States | 01 Sep 2011 | |
Relapse multiple myeloma | Phase 1 | United States | 01 Sep 2011 |
Phase 1 | 39 | sstqxenggu(pmpiqntmrb) = rbmtmjurnj jchojlrzoy (ggnhfwunml ) View more | Negative | 04 Feb 2019 |